Tag Archives: therapy

4 stocks to watch (PEIX, TSRA, LDK, GERN)

Posted on November 16, 2011 by Cameron White

In this report: Pacific Ethanol (NASDAQ:PEIX), Tessera Technologies (NASDAQ:TSRA), LDK Solar (NYSE:LDK) and Geron Corp. (NASDAQ:GERN).

Pacific Ethanol (NASDAQ:PEIX) is trading more than 24 percent higher today at $1.65 per share. The company announced that i had retired in full …

Posted in Latest Headlines, Reports | Tagged agreement, analyst, commercial, common stock, company, convertible notes, cut, downgraded, estimate, GERN, Geron Corp., gross margin, guidance, Hold, Kaufman Bros, LDK, LDK Solar, license, NASDAQ, NASDAQ:GERN, NASDAQ:PEIX, NASDAQ:TSRA, NYSE, NYSE:LDK, outlook, Pacific Ethanol, patents, patients, PEIX, rating, restructuring, revenue, Samsung Electronics, sell, Speculative Buy, stem cell, strong buy, technology, Tessera Technologies, therapy, trading, TSRA, WBB Securities | Comments Off

What the fuss Geron, Headwaters and Jacobs Engineering?

Posted on November 15, 2011 by Martin Timble

In this report: Geron Corporation (NASDAQ:GERN), Headwaters Inc. (NYSE:HW) and Jacobs Engineering Group (NYSE:JEC).

Geron Corporation (NASDAQ:GERN) shares plummeted today after the company said that it would ditch stem cell research due to high costs and commercial uncertainties. The company …

Posted in Latest Headlines, Reports | Tagged analyst, bought back, buy back, company, enrolling, estimates, expectations, expense, GERN, Geron Corporation, Headwaters Inc., HW, interest, Jacobs Engineering Group, JEC, NASDAQ, NASDAQ:GERN, notes, NYSE, NYSE:HW, NYSE:JEC, outstanding, patients, profit, research, restructuring, revenue, shares, spinal cord, stem cell, therapy, Wall Street | Comments Off

Big time losers and the reasons why (TRGT, XIDE, AMLN)

Posted on November 8, 2011 by Cameron White

In this report: Targacept Inc. (NASDAQ:TRGT), Exide Technologies (NASDAQ:XIDE) and Amylin Pharmaceuticals (NASDAQ:AMLN).

Targacept Inc. (NASDAQ:TRGT) has dropped by over 56 percent today after the company announced that its experimental drug TC-5214 failed to meet expectations in a trial to …

Posted in Main Post, Reports | Tagged AMLN, Amylin Pharmaceuticals, clinical trial, company, diabetes, drug, Eli Lilly and Co (NYSE:LLY), Exide Technologies, expectations, fiscal, guidance, NASDAQ, NASDAQ:AMLN, NASDAQ:TRGT, NASDAQ:XIDE, net sales, operating income, partnership, patients, payments, Phase 3, preliminary, products, quarter, results, revenue, severe depression, Targacept Inc., therapy, treat, TRGT, trial, XIDA | Comments Off

Big time losers and the reasons why (CALX, VRUS, BAS, TZOO)

Posted on October 21, 2011 by Martin Timble

In this report: Calix Inc. (NYSE:CALX), Pharmasset Inc. (NASDAQ:VRUS), Basic Energy Services (NYSE:BAS) and Travelzoo Inc. (NASDAQ:TZOO).

Calix Inc. (NYSE:CALX) has dropped more than 21 percent today after the company’s latest quarterly results. The company reported a third quarter profit …

Posted in Latest Headlines, Reports | Tagged Abbott Laboratories, ABT, BAS, Basic Energy Services, CALX, communications software, company, earnings, expectations, hepatitis C, interferon, investors, NASDAQ, NASDAQ:TZOO, NASDAQ:VRUS, net income, net loss, NYSE, NYSE:ABT, NYSE:BAS, NYSE:CALX, patients, Pharmasset Inc., profitCalix Inc., quarterly, results, revenue, spike, study, therapy, trades, Travelzoo Inc., TZOO, VRUS | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.